Introduction
============

Laryngeal squamous cell carcinoma (LSCC) is one of the most common malignancies that remains as a significant cause of morbidity and mortality in head and neck.[@b1-ott-9-7177] It is estimated that the new cases of laryngeal cancer expected among men and women in China in 2015 are 23,700 and 2,600, respectively; and the estimated number of deaths from laryngeal cancer is about 14,500.[@b2-ott-9-7177] Despite improvements in therapeutic modalities, the American Cancer Society indicates that there is a trend toward a decreasing 5-year survival rate among patients with laryngeal cancer in the recent years.[@b3-ott-9-7177] Thus, identification of novel and effective biomarkers for prediction of LSCC patients with poor prognosis or at high risk of early recurrence would be of great significance and may be beneficial for the development of effective therapeutic schemes.

Inflammation has been regarded as a hallmark of carcinogenesis and affects many aspects of malignancy, including initiation, development, and metastasis.[@b4-ott-9-7177] It is reported that LSCC patients have a significant increase of inflammatory response compared with chronic hypertrophic laryngitis and normal controls.[@b5-ott-9-7177] It is known that exposure to tobacco smoke and alcohol are detrimental factors for LSCC. Mucosal damage from chronic tobacco and alcohol exposure has been well characterized. Toxins in cigarette smoke and alcohol metabolites can impair innate defenses against pathogens, modulate antigen presentation, and induce chronic inflammation at mucosal surfaces; they may also cause mutations and malignant transformation through binding to the DNA of mucosal cells.[@b6-ott-9-7177],[@b7-ott-9-7177] The infiltration of immune cells in LSCC, such as mast cells, neutrophils, and macrophage, may produce small molecules including cytokines, chemokines, and growth factors which can promote carcinogenesis and tumor angiogenesis and enable tumors to evade the host immune response as well as recruit more immune cells.[@b8-ott-9-7177] What's more, squamous cell carcinomas themselves can also overexpress cytokines with pro-inflammatory, proangiogenic, and immunoregulatory activity.[@b5-ott-9-7177],[@b9-ott-9-7177] Additionally, studies showed that there might be genetic alterations associated with chronic inflammation in LSCC, such as the p53 mutation, and the upregulation of various inflammation-related genes, including interleukin (IL)-8, IL-6, cyclooxygenase-2, and so on.[@b10-ott-9-7177],[@b11-ott-9-7177]

Cumulating evidence suggests that increased systemic inflammation might represent a stage-independent unfavorable prognostic factor in different types of cancer.[@b1-ott-9-7177],[@b12-ott-9-7177]--[@b15-ott-9-7177] Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), which reflect the systemic inflammation, are readily available and effective predictors of poor survival outcome across various cancers, including intrahepatic cholangiocarcinoma,[@b12-ott-9-7177] breast cancer,[@b13-ott-9-7177] colorectal cancer,[@b14-ott-9-7177] LSCC,[@b1-ott-9-7177],[@b15-ott-9-7177] and so on. In contrast, a high density of tumor infiltrating lymphocytes (TILs), which represents a robust intratumoral inflammatory response, is recognized as a good prognostic marker in multiple malignancies, such as breast cancer,[@b16-ott-9-7177] colon cancer,[@b17-ott-9-7177] and gastric cancer.[@b18-ott-9-7177] Recent studies have also demonstrated that high levels of intratumoral immune cell infiltrates in head and neck squamous cell carcinomas are associated with superior patient survival.[@b19-ott-9-7177]--[@b22-ott-9-7177]

So far, the present studies about LSCC have evaluated either the local or systemic inflammatory responses for their predictive abilities independently. Combination of both the systemic and local inflammation may provide more exact information to clinicians about the prognosis of LSCC. To the best of our knowledge, this is the first study to examine both the types of inflammatory processes and outcomes in LSCC with postoperative radiotherapy. Here, we examine both systemic and local inflammation, clinicopathologic data, and outcomes in a series of LSCC patients.

Methods
=======

Patients
--------

A retrospective study was conducted using a primary cohort of patients with LSCC who underwent surgical resection at the Department of Otorhinolaryngology, Eye, Ear, Nose, and Throat Hospital of Fudan University from January 2008 to August 2012, and then had postoperative radiotherapy or chemoradiotherapy at the Department of Radiation Oncology, Eye, Ear, Nose, and Throat Hospital of Fudan University as there were adverse features (eg, extracapsular nodal spread, positive margins, pT4 primary, N2 or N3 nodal disease, vascular embolism, and perineural invasion). Inclusion criteria were the following: histopathologically proven LSCC; complete clinical, laboratory, imaging, follow-up data, and available pathologic slides; no history of anticancer therapy; patients were treated with curative intent; no history of other malignancies, and no distant metastasis. Data relating to diagnosis, histopathological features, patient characteristics, treatment, and outcomes were collected, as well as the follow-up data, including any cancer recurrence. Approval for this study was provided by the relevant Human Research Ethics Committee of the Eye, Ear, Nose, and Throat Hospital, Fudan University. The ethics committee of the Eye, Ear, Nose, and Throat Hospital, Fudan University, did not require written informed consent be obtained from all patients, as this was a retrospective study, and all data was anonymous.

Assessment of intratumoral inflammation
---------------------------------------

Hematoxylin and eosin-stained tissue sections of formalin-fixed paraffin-embedded tumor specimens were collected for all patients. One pathologist evaluated all available sections for every patient and selected the slide with the highest TILs density.[@b17-ott-9-7177] From this slide, two certified pathologists (WJZ and SYW) scored the average TILs density within tumor areas that were composed of \>60% of neoplastic cells.[@b17-ott-9-7177] Areas of adenoma, ulceration, and necrosis were excluded from the analysis.[@b17-ott-9-7177] TILs density was calculated as the ratio of the area occupied by mononuclear cell infiltrates to the entire stromal area (% TIL = area occupied by mononuclear cells in tumor stromal/total stromal area).[@b16-ott-9-7177] TILs density was assessed at ×100 and ×400 magnification, and scored as 1+ (low, \<30%), 2+ (moderate, ≥30% and \<60%), or 3+ (abundant, ≥60%) by each observer.[@b20-ott-9-7177] Pathologists were blinded from each other's assessment and patient outcomes. All the patients were assigned an overall TILs density of "high" (2+ or 3+) or "low" (1+) by the two pathologists,[@b17-ott-9-7177] and consensus was reached when there was a discrepancy.

Assessment of systemic inflammation
-----------------------------------

Preoperative neutrophil, platelet, and lymphocyte counts were obtained from whole blood count samples taken within 2 weeks prior to primary tumor surgery for each patient. NLR was calculated as the absolute neutrophil count divided by the absolute lymphocyte count, whereas PLR was calculated as the absolute platelet count divided by the absolute lymphocyte count.

Statistical methods
-------------------

Statistical analyses were performed using IBM SPSS version 19.0 (IBM, Armonk, NY, USA) and GraphPad VR Prism 6 (GraphPad Software Inc., La Jolla, CA, USA). Overall survival (OS) was defined as time from the date of diagnosis to death from any cause. Relapse-free survival (RFS) was calculated as time to relapse of LSCC, excluding death events or diagnosis of a second malignancy. Survival curves for OS and RFS were analyzed using the Kaplan--Meier method and compared using the log-rank test. The best cutoffs for NLR and PLR were determined using a time-dependent receiver operating characteristic curve. Proportions were compared using the *χ*^2^ method and Fisher's exact test. Multivariate analyses of survival were performed using the Cox proportional hazards model; data were presented as hazard ratios (HRs) and 95% confidence intervals (CIs). Two-tailed *P*-values \<0.05 were considered to be statistically significant.

Results
=======

Patients
--------

A total of 120 patients were eligible for the study. The mean age at diagnosis was 60.6±8.6 years. There were 118 men (98.3%) and 2 women (1.7%). The majority of patients were current or ex-smokers (n=90, 75.0%), and 66 (55.0%) had a history of alcohol intake. The site of the primary tumor was almost distributed between the glottis (63 \[52.5%\]) and supraglottic larynx (52 \[43.3%\]), and only five persons (4.2%) had subglottic cancer. Sixty patients (50.0%) were in T1--T2 stage and the others (50.0%) were in T3--T4 stage. Eighty-two patients were in N0 stage (68.3%), with 38 patients (31.7%) in N1--N3 stage. Among the 63 patients with glottis cancer, only 12 patients were in T1 stage and the other 51 patients were in T2--T4 stage, which may invade the supraglottic or subglottic region, paraglottic space, and other nearby structures. All the 52 patients with supraglottic cancer were in T2--T4 stage. Among the 38 patients with cervical node metastasis, only 11 patients had glottis cancer and all the others had supraglottic cancer. Additionally, all the 11 patients with glottis cancer who also had cervical node metastasis were all in T2--T4 stage. Surgical procedures included total laryngectomy (55 cases, 45.8%), partial laryngectomy (54 cases, 45.0%), and CO~2~ laser surgery (11 cases, 9.2%). All the patients had postoperative radiotherapy, in which 49 patients had chemotherapy as well. Patient and tumor characteristics were listed in [Table 1](#t1-ott-9-7177){ref-type="table"} for more details. No significant correlations were found between NLR, PLR, and clinicopathological characteristics in our study ([Table S1](#SD1-ott-9-7177){ref-type="supplementary-material"}).

Survival analyses based on markers of systemic inflammation
-----------------------------------------------------------

In all the 120 LSCC patients, the mean survival time was 40.1±14.9 months (from 5.0 to 91.0 months), and mean RFS was 32.7±19.2 months (from 4.0 to 64.0 months). Using time-dependent receiver operating characteristic curves, we determined a cutoff NLR value of 2.79 and a cutoff PLR value of 112 for prognosis in LSCC patients. The mean OS time was 41.1±14.9 months in the low NLR group and 38.3±14.7 months in the high NLR group. As shown in [Figure 1A](#f1-ott-9-7177){ref-type="fig"}, the 5-year OS rate of the patients with an NLR ≥2.79 was significantly lower than that of patients with an NLR \<2.79 (44.1% vs 57.6%, *P*=0.020). We also found that an NLR ≥2.79 was significantly correlated with LSCC recurrence (NLR \<2.79 vs NLR ≥2.79, mean RFS 34.7±20.0 vs 29.0±17.2 months). The 5-year RFS rates in the high NLR group were significantly lower compared with the low NLR group (42.7% vs 65.9%, *P*=0.017, [Figure 1B](#f1-ott-9-7177){ref-type="fig"}).

The survival analysis also highlighted the poor outcome of the patients with an elevated PLR. A high pretreatment PLR was found to be associated with worse OS (PLR \<112 vs PLR ≥112, mean OS 42.2±14.5 vs 38.2±15.0 months). The 5-year OS rates in the low PLR group were significantly higher compared with the high PLR group (77.8% vs 28.7%, *P*=0.0007, [Figure 2A](#f2-ott-9-7177){ref-type="fig"}). Moreover, high pretreatment PLR was also associated with worse RFS (PLR \<112 vs PLR ≥112, mean RFS 37.0±18.2 vs 28.7±19.4 months). The 5-year RFS rate in the high PLR group (41.8%) was significantly lower compared with the low PLR group (62.5%, *P*=0.0007, [Figure 2B](#f2-ott-9-7177){ref-type="fig"}). These data suggested that high PLR may be a marker of early LSCC recurrence.

Survival analyses based on marker of intratumoral inflammation
--------------------------------------------------------------

In our study, 56 patients had low TILs (\<30%, [Figure 3A](#f3-ott-9-7177){ref-type="fig"}), 41 patients had moderate TILs (≥30% and \<60%, [Figure 3B](#f3-ott-9-7177){ref-type="fig"}), and 23 patients had abundant TILs (≥60%, [Figure 3C](#f3-ott-9-7177){ref-type="fig"}). All the patients were divided into two groups according to the TILs density: the low TILs group (n=56) and the high TILs group (n=64). The mean OS time was 37.5±16.3 months in the low TILs group and was 42.5±13.1 months in the high TILs group. The 5-year OS rates in the low TILs group (34.0%) were significantly lower compared with the high TILs group (70.1%, *P*=0.0199, [Figure 4A](#f4-ott-9-7177){ref-type="fig"}). Hence, the level of stromal TILs was strongly associated with improved survival outcome of the patients. We also found that a low TILs density was significantly correlated with LSCC recurrence (low vs high TILs, mean RFS 27.3±19.0 vs 37.5±18.2 months). The 5-year RFS rate in the high TILs group was significantly higher compared with the low TILs group (68.5% vs 33.1%, *P*=0.0047, [Figure 4B](#f4-ott-9-7177){ref-type="fig"}). The data indicated that low TILs density may predict early LSCC recurrence. What is more, no significant correlations were found between NLR and TILs, as well as between PLR and TILs (*P*\>0.05, [Table S1](#SD1-ott-9-7177){ref-type="supplementary-material"}).

Univariable and multivariable analyses
--------------------------------------

Clinicopathological parameters, including NLR, PLR, and TILs density, were evaluated to identify predictors of LSCC patients' OS and RFS. The results for the statistically significant prognostic factors for OS, which were identified using univariate and multivariate analyses, were presented in [Table 2](#t2-ott-9-7177){ref-type="table"}. A high pretreatment NLR or PLR and a low TILs density were identified as a predictor of poor prognosis. The multivariate analyses identified that a high PLR (*P*=0.004, HR: 2.801, 95% CI: 1.403--5.595) and a low TILs density (*P*=0.019, HR: 0.471, 95% CI: 0.251--0.884) were significantly correlated with worse OS ([Table 2](#t2-ott-9-7177){ref-type="table"}). Hence, high PLR and low TILs density were independent predictors of poor prognosis.

The statistically significant factors for RFS that were identified using univariate and multivariate analyses were presented in [Table 3](#t3-ott-9-7177){ref-type="table"}. A high pretreatment NLR or PLR and a low TILs density were identified as a predictor of tumor recurrence. The multivariate analyses identified high PLR (*P*=0.002, HR: 2.622, 95% CI: 1.431--4.804) and low TILs density (*P*=0.009, HR: 0.473, 95% CI: 0.269--0.832) as independent predictors of tumor recurrence ([Table 3](#t3-ott-9-7177){ref-type="table"}). These results suggested that high PLR values and low TILs density were strong predictors of tumor recurrence. Hence, LSCC patients with high PLR values and low TILs density should be closely followed for LSCC recurrence.

Discussion
==========

Up to now, robust evidence suggests that not only the tumor behavior but also the host immune response may influence tumor outcome.[@b23-ott-9-7177] Tumor-related systemic inflammatory response plays a crucial role in tumor growth and metastasis and is an important predictor of tumor outcome. There has been an increasing evidence that elevated NLR and PLR, which may be a simple way to assess the systemic inflammatory response, are correlated with advanced stage and poor prognosis in patients with various solid tumors.[@b1-ott-9-7177],[@b12-ott-9-7177]--[@b15-ott-9-7177] Rassouli et al[@b24-ott-9-7177] showed that pretreatment NLR and PLR could be used in head and neck squamous cell carcinomas as prognosticators of survival and recurrence independent of TNM staging. Both Tu et al[@b1-ott-9-7177] and Fu et al[@b15-ott-9-7177] recently demonstrated that an elevated preoperative NLR was an independent predictor of recurrence and poor OS in patients with LSCC. In our study, we also found that the pretreatment NLR had potential for use as a predictor of survival, and high NLR (≥2.79) showed notable correlation with early recurrence and poor OS of LSCC patients. Hence, the pretreatment NLR may be a useful parameter to predict survival in LSCC patients.

The prognostic role of pretreatment PLR in patients with LSCC has, until now, been rarely investigated. We found an elevated PLR might be a significant prognostic factor in LSCC patients with both surgery and postoperative radiotherapy. The PLR values \$112 showed the greatest correlation with worse OS and early recurrence, and high PLR was independent predictor of poor prognosis. In our study, both high NLR and PLR values were associated with decreased OS (HR: 1.99, 95% CI: 1.09--3.65, *P*=0.025 and HR: 3.04, 95% CI: 1.53--6.04, *P*=0.001, respectively) and RFS (HR: 1.92, 95% CI: 1.11--3.34, *P*=0.020 and HR: 2.70, 95% CI: 1.48--4.94, *P*=0.001, respectively) in univariate analysis, but only PLR remained significant in multivariate analysis for both OS and RFS (HR: 2.80, 95% CI: 1.40--5.60, *P*=0.004 and HR: 2.62, 95% CI: 1.43--4.80, *P*=0.002, respectively). These results indicated that pretreatment PLR was superior to NLR as an adverse prognostic factor in patients with LSCC, which was in accordance with Neofytou's report in colorectal cancer.[@b25-ott-9-7177] Our results confirmed that pretreatment PLR could be reliable prognostic factors for patients with LSCC.

Although the elevated NLR and PLR appear to associate with poor RFS and OS are confirmed by many studies, the underlying mechanisms remain poorly understood. One possible explanation is that the cancer-related systemic inflammatory responses are associated with alterations in circulating blood cell distribution with a relative neutrophilia and thrombocytosis, as well as a relative depletion of lymphocytes.[@b24-ott-9-7177],[@b26-ott-9-7177] The increased neutrophils may produce and secrete angiogenesis-regulating growth factors, cytokines, chemokines, and proteases that could promote tumor growth and progression.[@b27-ott-9-7177]--[@b30-ott-9-7177] Moreover, as lymphocytes have a crucial role in tumor immune surveillance as well as inhibition of tumor cell proliferation and metastasis, lymphocytopenia is assumed to reflect a generally depressed state of the host immune system.[@b24-ott-9-7177],[@b26-ott-9-7177],[@b31-ott-9-7177] It has been reported that lymphocytes in patients with head and neck cancer have significantly higher rates of apoptosis compared with normal controls,[@b32-ott-9-7177] and the cytolytic activity of lymphocytes may be suppressed by neutrophilia.[@b33-ott-9-7177] Platelets have been shown to have an important role in angiogenesis, tumor cell growth, and dissemination.[@b34-ott-9-7177] The differentiation of megakaryocytes to platelets could be triggered by the tumor-associated inflammatory mediators, such as IL-1, IL-3, and IL-6.[@b35-ott-9-7177] The elevated peripheral blood platelets then could accelerate tumor cell growth and dissemination through promotion of angiogenesis, increase of microvessel permeability, production of growth factors and adhesion molecules, as well as protection of the circulating cancer cells from the immune system.[@b34-ott-9-7177]--[@b37-ott-9-7177] Hence, high NLR and PLR values may indicate an impaired host antitumor immune status. Overall, cancer-related systemic inflammation with an elevated high NLR and PLR values may potentially create a tumor-favorable microenvironment that may promote the tumor proliferation and metastasis.

Tumor infiltration by chronic inflammatory cells comprises lymphocytes, plasma cells, and macrophages.[@b17-ott-9-7177] TILs are the major type of infiltrating immune cells and are represented by T cells, B cells, and natural killer cells.[@b18-ott-9-7177] TILs are considered a manifestation of the host immune response against tumor cells, and several studies have already reported the potential of TILs as prognostic parameters in various human malignancies.[@b18-ott-9-7177],[@b20-ott-9-7177],[@b38-ott-9-7177],[@b39-ott-9-7177] So far, there are several methods to assess tumor immune response through lymphocytic infiltrations on formalin-fixed paraffin-embedded sections, such as morphologic evaluation of TILs,[@b20-ott-9-7177] immunoscoring of T-cell subpopulations (eg, CD3^+^ or CD8^+^),[@b40-ott-9-7177] and immunophenotyping.[@b41-ott-9-7177] In our study, only the morphologic evaluation of TILs is performed. It is demonstrated that a high density of TILs is recognized as a good prognostic marker in multiple malignancies.[@b16-ott-9-7177],[@b18-ott-9-7177],[@b20-ott-9-7177],[@b39-ott-9-7177] Thus, the morphologic evaluation of TILs, which is simple and could be assessed in routine clinical practice without extra cost, may help the doctors to quickly identify patients at high risk of recurrence and early death.

The favorable prognostic role of abundant TILs has been explored in several tumors.[@b18-ott-9-7177],[@b20-ott-9-7177],[@b38-ott-9-7177],[@b39-ott-9-7177] Vassilakopoulou et al[@b20-ott-9-7177] reported that increased TILs density was associated with favorable outcome in LSCC. In our study, high TILs density was significantly associated with improved OS and RFS (*P*=0.0199, 0.0047, respectively; [Figure 4](#f4-ott-9-7177){ref-type="fig"}) of the patients and retained significance in multivariate analysis. Hence, assessment of TILs could be useful in the prediction of LSCC. Moreover, our results showed that NLR and PLR were not correlated with TILs density (*P*\>0.05, [Table S1](#SD1-ott-9-7177){ref-type="supplementary-material"}). Turner et al[@b17-ott-9-7177] also demonstrated that local and systemic inflammatory responses appeared to be largely independent of each other in colon cancer; although there was a trend toward an inverse relationship between local inflammation and systemic inflammation, it did not achieve statistical significance.

There are several limitations in the present study. First, this study is based on only 120 eligible patients, and these analyses need to be validated in a larger cohort of patients. Because LSCC is a male-dominated disease,[@b2-ott-9-7177],[@b3-ott-9-7177] it is inevitable that there is a significant sex bias in our patient cohort. Second, due to the limited number of enrolled patients, the stratified analysis on the basis of the combination of systemic and local inflammation is not done in our study. Finally, it is a retrospective study and is conducted at a single institution. Thus, our findings need to be validated in prospective analysis.

Conclusion
==========

High NLR and PLR, biomarkers of the host systemic inflammatory response, are correlated with poor OS and RFS. Conversely, high TILs density, which represents the local inflammation, is predictive of longer OS and RFS. Our results also indicated that PLR and TILs density are significant independent prognostic factors in LSCC patients with both surgery and postoperative radiotherapy. Hence, the inexpensive and readily available biomarkers of systemic and local inflammation, especially PLR and TILs density, could be used for risk assessment in clinical practice for individual treatment and surveillance of LSCC.

Supplementary material
======================

###### 

Correlation between NLR, PLR, and clinicopathological characteristics in LSCC (n=120)

  Clinicopathological indexes   NLR   *P*-values   PLR     *P*-values        
  ----------------------------- ----- ------------ ------- ------------ ---- -------
  Age (years)                                      0.121                     0.596
   \<60                         45    18                   29           34   
   ≥60                          33    24                   29           28   
  Sex                                              0.121                     0.496
   Male                         78    40                   58           60   
   Female                       0     2                    0            2    
  Smoking history                                  0.507                     0.140
   Yes                          57    33                   47           43   
   No                           21    9                    11           19   
  Drinking history                                 0.729                     0.485
   Yes                          42    24                   30           36   
   No                           36    18                   28           26   
  Tumor subsite                                    0.298                     0.081
   Supraglottic                 30    22                   21           31   
   Glottic                      45    18                   36           27   
   Subglottic                   3     2                    1            4    
  T stage                                          1                         0.144
   T1--T2                       39    21                   33           27   
   T3--T4                       39    21                   25           35   
  N stage                                          0.593                     0.804
   N0                           52    30                   39           43   
   N1--N3                       26    12                   19           19   
  TNM stages                                       0.581                     0.402
   I--II                        24    15                   21           18   
   III--IV                      54    27                   37           44   
  Histological grade                               0.046                     0.479
   Well                         20    4                    10           14   
   Moderately                   49    35                   41           44   
   Poorly                       9     3                    7            4    
  TILs density                                     0.818                     0.449
   High                         41    23                   33           31   
   Low                          37    19                   25           31   

**Abbreviations:** NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LSCC, laryngeal squamous cell carcinoma; TILs, tumor infiltrating lymphocytes.

The present study was supported by the Science and Technology Commission Foundation of Shanghai, China (grant number 12JC1402102).
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![Kaplan--Meier survival curves for (**A**) OS and (**B**) RFS of 120 LSCC patients stratified as NLR \<2.79 vs NLR ≥2.79.\
**Abbreviations:** OS, overall survival; RFS, recurrence-free survival; LSCC, laryngeal squamous cell carcinoma; NLR, neutrophil-to-lymphocyte ratio.](ott-9-7177Fig1){#f1-ott-9-7177}

![Kaplan--Meier survival curves for OS (**A**) and RFS (**B**) according to PLR (\<112 vs ≥112).\
**Notes:** The PLR was significantly related to the (**A**) OS (*P*=0.0007) and (**B**) RFS (*P*=0.0007).\
**Abbreviations:** OS, overall survival; RFS, recurrence-free survival; PLR, platelet-to-lymphocyte ratio.](ott-9-7177Fig2){#f2-ott-9-7177}

![Stromal TILs in laryngeal squamous cell carcinomas.\
**Notes:** (**A**) Low, TILs occupy an area of \<30% of the entire stromal area; (**B**) moderate, TILs occupy an area of 30%--60% of the entire stromal area; and (**C**) abundant, TILs occupy an area of ≥60% of the entire stromal area (H&E, ×100).\
**Abbreviations:** TILs, tumor infiltrating lymphocytes; H&E, hematoxylin and eosin.](ott-9-7177Fig3){#f3-ott-9-7177}

![Kaplan--Meier curves showed that high TILs density correlated with superior OS (**A**) and RFS (**B**) of patients with LSCC, *P*-values calculated by log-rank test.\
**Abbreviations:** TILs, tumor infiltrating lymphocytes; LSCC, laryngeal squamous cell carcinoma; OS, overall survival; RFS, recurrence-free survival.](ott-9-7177Fig4){#f4-ott-9-7177}

###### 

Patients' clinicopathological characteristics, n=120

  Characteristics                                                        Values
  ---------------------------------------------------------------------- ----------------------------------
  Age (years), mean ± SD (range)                                         60.6±8.6 (40--81)
  Sex (male/female)                                                      118 (98.3%)/2 (1.7%)
  Smoking (no/yes)                                                       30 (25.0%)/90 (75%)
  Drinking (no/yes)                                                      54 (45%)/66 (55%)
  Tumor subsite (supraglottic/glottic/subglottic)                        52 (43.3%)/63 (52.5%)/5 (4.2%)
  T stage (T1--T2/T3--T4)                                                60 (50%)/60 (50%)
  N stage (N0/N1--N3)                                                    82 (68.3%)/38 (31.7%)
  TNM stages (I--II/III--IV)[a](#tfn2-ott-9-7177){ref-type="table-fn"}   39 (32.5%)/81 (67.5%)
  Pathological type (highly/moderately/poorly)                           24 (20.0%)/84 (70.0%)/12 (10.0%)
  NLR (\<2.79/≥2.79)                                                     78 (65.0%)/42 (35.0%)
  PLR (\<112/≥112)                                                       58 (48.3%)/62 (51.7%)
  TILs density (low/high)                                                56 (46.7%)/64 (53.3%)

**Notes:** Values in parentheses are percentages unless indicated otherwise;

according to the 7th American Joint Committee on Cancer staging system.

**Abbreviations:** NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; TILs, tumor infiltrating lymphocytes.

###### 

Univariate and multivariate analyses of factors in relation to overall survival using the Cox proportional hazards model (n=120)

  ------------------------------------------------------------------------------------------------------------
  Variables                                                                    OS                      
  ---------------------------------------------------------------------------- ----------------------- -------
  Univariate analysis                                                                                  

   Age (≤60 vs \>60)                                                           1.137 (0.624--2.072)    0.675

   Smoking (no vs yes)                                                         0.720 (0.365--1.421)    0.344

   Drinking (no vs yes)                                                        0.929 (0.511--1.690)    0.810

   Tumor subsite (supraglottic/glottic/subglottic)                             0.601 (0.179--2.020)\   0.436
                                                                               0.472 (0.139--1.600)    

   T stage (T1 + T2 vs T3 + T4)                                                0.885 (0.486--1.613)    0.690

   N stage (N0 vs N1--N3)                                                      0.881 (0.459--1.690)    0.703

   TNM stages (I + II vs III + IV)[a](#tfn4-ott-9-7177){ref-type="table-fn"}   1.043 (0.551--1.974)    0.897

   Pathological type (highly/moderately/poorly)                                0.414 (0.148--1.159)\   0.128
                                                                               0.434 (0.189--1.000)    

   NLR (low vs high)                                                           1.994 (1.089--3.649)    0.025

   PLR (low vs high)                                                           3.044 (1.534--6.041)    0.001

   TILs density (low vs high)                                                  0.493 (0.267--0.909)    0.024

  Multivariate analysis                                                                                

   PLR (low vs high)                                                           2.801 (1.403--5.595)    0.004

   TILs density (low vs high)                                                  0.471 (0.251--0.884)    0.019
  ------------------------------------------------------------------------------------------------------------

**Note:**

According to the 7th American Joint Committee on Cancer staging system.

**Abbreviations:** NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; TILs, tumor infiltrating lymphocytes; OS, overall survival; HR, hazard ratio; CI, confidence interval.

###### 

Univariate and multivariate analyses of factors in relation to recurrence-free survival using the Cox proportional hazards model (n=120)

  ------------------------------------------------------------------------------------------------------------
  Variables                                                                    RFS                     
  ---------------------------------------------------------------------------- ----------------------- -------
  Univariate analysis                                                                                  

   Age (≤60 vs \>60)                                                           1.066 (0.615--1.847)    0.820

   Smoking (no vs yes)                                                         0.783 (0.421--1.458)    0.441

   Drinking (no vs yes)                                                        0.929 (0.536--1.611)    0.793

   Tumor subsite (supraglottic/glottic/subglottic)                             0.712 (0.214--2.375)\   0.640
                                                                               0.597 (0.180--1.982)    

   T stage (T1 + T2 vs T3 + T4)                                                1.127 (0.650--1.955)    0.670

   N stage (N0 vs N1--N3)                                                      1.117 (0.624--1.999)    0.710

   TNM stages (I + II vs III + IV)[a](#tfn6-ott-9-7177){ref-type="table-fn"}   1.240 (0.679--2.265)    0.485

   Pathological type (highly/moderately/poorly)                                0.656 (0.232--1.853)\   0.721
                                                                               0.743 (0.313--1.765)    

   NLR (low vs high)                                                           1.921 (1.107--3.335)    0.020

   PLR (low vs high)                                                           2.698 (1.475--4.938)    0.001

   TILs density (low vs high)                                                  0.456 (0.260--0.802)    0.006

  Multivariate analysis                                                                                

   PLR (low vs high)                                                           2.622 (1.431--4.804)    0.002

   TILs density (low vs high)                                                  0.473 (0.269--0.832)    0.009
  ------------------------------------------------------------------------------------------------------------

**Note:**

According to the 7th American Joint Committee on Cancer staging system.

**Abbreviations:** NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; TILs, tumor infiltrating lymphocytes; RFS, recurrence-free survival; HR, hazard ratio; CI, confidence interval.
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